Table 2.
The relationship between HLA-E and clinical parameters.
| Characteristics | Expression of HLA-E | ||
|---|---|---|---|
| Low expression n (%) | High expression n (%) | p | |
| Age (years) | |||
| ≤65 | 7 (43.8%) | 9 (56.2%) | 0.464 |
| >65 | 8 (57.1%) | 6 (42.9%) | |
| Gender | |||
| Male | 8 (44.4%) | 10 (55.6%) | 0.456 |
| female | 7 (58.3%) | 5 (41.7%) | |
| R-ISS staging system | |||
| Early stage | |||
| (stage I–II) | 9 (75%) | 3 (25%) | 0.025 |
| Advanced stage | |||
| (stage III) | 6 (33.3%) | 12 (66.7%) | |
| Cytogenetics risk | |||
| Standard risk | 15 (71.4%) | 6 (28.6%) | 0.000 |
| High risk | 0 (0%) | 9 (100%) | |
*The cutoff value of HLA-E was 31.77 based on the median expression value.
Bold value means having statistically significant.